ASEC 2025 Conference

The 6th International Electronic Conference on Applied Sciences

09–11 December 2025 | Online

MDPI

Epigenetic Switches for Next-Generation Genomic Intervention: From Synthetic Biology to Personalized Medicine

Dave Purva, Chauhan Jhanvi, Maheta Shivam, Belim Sahir, Meghnathi Omish

Corresponding Author : Dr. Sheetal S. Buddhadev (sheetal.buddhadev@ngivbt.edu.in)

Faculty of Pharmacy, Noble University, Junagadh, Gujarat, India.

INTRODUCTION

Epigenetic disruptions have been identified as the main factors that lead to diseases, however, the existing therapies are often low in precision. Our suggestion is a framework that integrates CRISPR/dCas instruments with synthetic circuits to create programmable epigenetic switches. To enable more intelligent control, the system utilizes conditional guide RNAs, thus off-target effects are lowered. In the end, this approach opens up a possibility of very precise, individualized treatment of cancer and metabolic diseases.



METHOD

This methodology integrates a comprehensive review of CRISPR/dCas editors and synthetic guide RNAs to construct a conceptual three-layer epigenetic switch. The system functions through a signal input layer detecting specific triggers, activating a processing layer where cgRNA-based logic gates and dCas fusions direct precise chromatin modifications. This drives the output layer to execute reversible gene regulation aimed at restoring healthy chromatin patterns. The framework is finally evaluated against key literature metrics, specifically prioritizing locus specificity, dynamic range, and reversibility.



RESULTS & DISCUSSION

Precision editing with CRISPR/dCas9 and dCas12a fusions enables targeted chromatin remodeling, which allows for the activation of tumor suppressors or silencing of oncogenes without inducing double-strand breaks. Conditional guide RNAs introduce logical control (AND/OR/NOT) with substantial dynamic range, thereby enabling the modulation of components in metabolic and cytoskeletal pathways. Translational potential ranges from cancer to cardiovascular, metabolic, and neurodegenerative diseases, while principal translational barriers are addressed with non-viral delivery modalities that include lipid nanoparticles and exosomes. Personalized tools target aberrant methylation, histone dysregulation, and m6A modifications typical of disease-specific epigenetic alterations for programmable intervention.



CONCLUSION

Epigenetic switches are a game-changing blend of CRISPR/dCas accuracy and the versatility of synthetic biology. Such programmable elements make it possible to control, reversible, and even specific to a certain locus, modulate gene expression. Thanks to improving delivery routes and diminishing off-target effects, these switches will be the main drivers of most futuristic personalized medicine scenarios. In essence, they serve as a revolutionary platform for the therapy of cancer, metabolic diseases, and immune disorders.

REFERENCES

1. Kang H. et al., Logical regulation of endogenous gene expression using programmable gRNAs., NAR, 2024.
2. Dai W. et al., Epigenetics-targeted drugs: current paradigms and future challenges., STTT, 2024.
3. Li T. et al., CRISPR-Cas9 therapeutics: progress and prospects., STTT, 2023.
4. Sgro A., Blancafort P., Epigenome engineering: new technologies for precision medicine. NAR, 2020.